For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Asset impairment | - | 0* | 0 | 0 |
| Research and development | 178 | -1,163* | -333 | 98 |
| General and administrative | 880 | 1,332* | 957 | 787 |
| Total operating expenses | 1,058 | 168 | 624 | 885 |
| Loss from operations | -1,058 | -168* | -624 | -885 |
| Other income | - | 0* | 0 | 0 |
| Interest income, net | 103 | 93* | 156 | 123 |
| Total other income | 103 | 93* | 156 | 123 |
| Net loss | -955 | -76 | -468 | -762 |
| Basic EPS | -0.14 | -0.015 | -0.07 | -0.19 |
| Diluted EPS | -0.14 | -0.015 | -0.07 | -0.19 |
| Basic Average Shares | 6,729,855 | 4,908,164* | 6,241,658 | 4,021,276 |
| Diluted Average Shares | 6,729,855 | 4,908,164* | 6,241,658 | 4,021,276 |
MUSTANG BIO, INC. (MBIO)
MUSTANG BIO, INC. (MBIO)